Drug giant GlaxoSmithKline (LSE: GSK) is to shell out almost £1.6bn in settlement of legal issues, and it has just reported a £304m second-quarter loss.

Hardly the most obvious reason to buy the stock, you might think. But for ‘pairs’ traders it could present an interesting opportunity.

http://www.moneyweek.com/online-trading/spread-betting/spread-betting-glaxo-astrazeneca-pairs-trading-02913.aspx

Advertisement